MetiMedi Pharmaceuticals

Developing Unique Platform Technology
For Unmet Needs for Cancer Therapies and Beyond


MetiMedi Pharmaceuticals


Our People

  • Management Team
  • Scientific Advisory Board
  • Hwan Mook Kim




  • Eun-Hee Ji


  • Chong Hwan Chang


  • Hyunseo Koo

    (Patent Attorney/Director)

  • Keele Park


  • Jong-Won Rhie

    (MD. Ph.D.)

  • Jeong-Heum Baek

    (MD. Ph.D.)

  • Elizabeth S. Song


  • Sang-Bae Han


  • Seung Hyun Oh

    (Ph.D. D.V.M. DKCLAM)

  • Kwagng Won Jeong



Cell Metabolic Reprogramming Platform (CMRP)
  • “ Tumors cells and effector T cells share dependencies for glucose, glutamine, tryptophan, or arginine.

  • a

    Tumor cells, by their extensive need of glucose, glutamine, tryptophan of arginine will impoverish the tumor area. This resource consumption from tumor cells will directly impact CD8 T cell metabolism leading to exhausted phenotype and indirectly, through metabolite secretion like for example lactate, stimulate the development of an immunosuppressive tumor micro-environment.
  • b

    At the opposite, if tumor cells have moderate metabolic demand, due to intrinsic characteristics or therapeutic manipulations, a fully functional anti-tumor immune response will mediated tumor elimination.”

Ref: Modified from Cerezo and Rocchi, Nature (2020) 11:964


Big Picture of MetiMedi Pharmaceuticals


  • · CRC : Colorectal cancer
  • · NASH : Non-alcoholic steatohepatitis
  • · RA : Rheumatoid arthritis
  • · AMD : Age-related macular degeneration

  • · AD : Alzheimer’s disease
  • · PD : Parkinson's disease
  • · MS : Multiple sclerosis
  • · IPF : Idiopathic pulmonary fibrosis


  • Status of Clinical trials



    Phase 2 clinical trial of Metimedi Pharmaceutical Co., Ltd.'s anti-cancer

    drug OMT-111(Pre-filled Syringe Formulation) was successfully processed as

    planned, and the last patient is currently on investigation.

    As soon as the last patient administration is completed, Phase 2 trial will be

    completed and reported to the Ministry of Food and Drug Satety of Korea after

    thorough clinical result analysis.

    In addition, Metimedi is planning to write a journal paper about the clinical trials

    and present to the global conference in the future. It will promote marketing

    activities for global pharmmaceutical companies.

    OMT-111 is further developed as an active tablet form named as Meti-101.

    Meti-101 will improve the patient's convenience of taking medicines and is applicable

    for various purposes.

    On Apr. 21, 2022, clinical 1b/2a trials of Meti-101 was approved by the Ministry of

    Food and Drug Safety of the Republic of Korea.

    On Aug. 11, 2022, Meti-101 was conditionally approved for the first IRB at

    Gachon University Gil Hospital. It is expected to receive final approval after

    submitting the documents requested by Gil Hospital.

    Once the final IRB is approved, the clinical trial contract will be singed and initiate

    the trial on registered 30 patients.

  • Chronic Inflammatory Diseases(CID) Patent Registrati...



    Metimedi Pharmaceutical Co., Ltd.'s CID (Chronic Inflammatory Disease) patent

    has been divided into three in the United States, and patent registration is under


    On Aug. 25, 2020, Metimedi's patents for multiple sclerosis, age-related macular

    degeneration, and non-alconholic steatohepatitis (NASH) were passed the U.S.

    Patent Office review and successfully registered in the U.S.

    Moreover, on Jan. 26, 2021, Metimedi gained the approval of its patent for

    Alzheimer's disease, Parkinson's disease, atherosclerosis, and inflammatory bowl

    dlsease in the U.S. Patent Office.

    Metimedi is planning to get more patents on other chronic inflammatory diseases.

  • Formulation Patent Registration Status



    On July. 7, 2022, the formulation patent for the anti-cancer drug of Metimedi

    Pharmaceutical Co., Ltd. was successfully registered in Mexico after passing the

    the patent registration by the Mexico Patent Office.

    As a result, Metimedi's anti-cancer drug formulation patent has been registered

    in two countries, the United States (registered March, 29, 2022) and Mexico.

    Currently,Metimedi is on the process of expanding its formulation patent further

    in 13 countries including European Patent Convention, Taiwan, and Japan.


Contact us

경기 의왕시 이미로 40 (인덕원IT밸리) D동 701

Eun-Hee Ji, Ph.D.

Chief Technology Officer

Phone  +82-32-205-0541


Heeyeol Yeom

Manager, Business Development

Phone  +82-32-205-0541